601results about How to "Improve clinical efficacy" patented technology

Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.

The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.

Disclosed are nucleic acid sequences, for example, DNA or RNA sequences, which encode an immunoglobulin Fc-Interferon-alpha fusion protein. The nucleic acid sequences can be inserted into a suitable expression vector and expressed in mammalian cells. Also disclosed is a family of immunoglobulin Fc-Interferon-alpha fusion proteins that can be produced by expression of such nucleic acid sequences. Also disclosed are methods of using such nucleic acid sequences and / or fusion proteins for treating conditions, for example, hepatitis, which are alleviated by the administration of interferon-alpha.

Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.

Treating of localized bacterial infection, comprising locally applying Taurolidine to the infection. A device for insertion into the body, the device comprising Taurolidine to render the device infection resistant. A medication for treating bacterial infections, comprising Taurolidine carried by one of: gels, liquid, thixotropic gels, colloidal mixtures, dispensal suspensions, injectable polymers, or a microparticle. A method for treating blood, comprising: removing blood from the body; treating the blood with Taurolidine; and returning the treated blood.

A biocompatible synthetic bone growth composition comprising a fibrillar collagen component and a calcium phosphate component. The composition is formed into particles, and then formed into a unitary article that may be provided at the site of a skeletal defect. An osteoinductive component may be further added, either before or after forming the unitary article. The composition may be formulated as a paste or putty and facilitates bone growth and / or repair.

Compounds and methods related to NIR molecular imaging, in-vitro and in-vivo functional imaging, therapy / efficacy monitoring, and cancer and metastatic activity imaging. Compounds and methods demonstrated pertain to the field of peripheral benzodiazepine receptor imaging, metabolic imaging, cellular respiration imaging, cellular proliferation imaging as targeted agents that incorporate signaling agents.

The invention discloses a total bufogenin extract with antitumor function and also discloses a preparation method of the extract and application thereof in the preparation of antitumor medicines. The total bufogenin extract of the invention is prepared by organic solvent extraction, column chromatography separation and purification of dried toadskin; the content of total bufogenin is over 80 percent, wherein the content of resibufogenin is over 12 percent, the content of cinobufagin is over 4 percent, and the content of bufotalin is over 10 percent. Compared with the prior art, the invention eliminates bufotenine alkaloid which has irritation, is easy to cause hypersensitivity but has no antitumor activity, efficiently collects the effective part of total bufogenin which has significant antitumor activity, therefore pharmacological action is stronger, the clinical curative effect is higher and the toxic and side effect is lower. The total bufogenin extract can be prepared into various pharmaceutical preparations for clinical application, therefore the invention has the functions of killing tumor cells, inducing differentiation and apoptosis of tumor cells, inhibiting the neovascularization of tumor cells and lowering the neoplasm metastasis rate, etc.

A hybrid catheter device for performing cutting action on a region of a tissue, using sequential laser and mechanical cutting processes, and incorporating an acoustic sensor on the end of the device, such that if a pulsed laser beam is used for the laser cutting, the absorption of that beam in the tissue being cut can provide information about the progress of the cut by means of the opto-acoustic effect. Other hybrid catheter devices incorporate blunt protrusions on the end of said device, but having sharp lateral edges, such that rotation of the catheter device generates mechanical cutting action in the tissue. The blunt protrusion ends prevents uncontrolled cutting in the forward motion. Other hybrid catheter devices enable controlled incisions into an organ wall, such as the duodenum, and held in place by means of an inflatable balloon. A dual-wavelength nail fungus treatment hybrid catheter is also shown.

This invention relates to cannabinoid-containing compositions, particularly cannabinoid-containing gel formulations and methods for the treatment of traumatic injury, e.g., strains, sprains and contusions, and disease conditions, e.g., arthritis, particularly osteoarthritis. The methods involve topically applying a cannabinoid or a cannabinoid-containing composition to a subject's skin near, or distant from, the area of the injury or the area affected by the disease condition, e.g., an arthritic joint. The cannabinoid-containing composition is preferably a pharmaceutically acceptable gel containing a therapeutically effective amount of a cannabinoid sufficient to alleviate the symptoms associate with the injury or disease condition.

The invention discloses a cefepime antibacterial drug comprising cefepime and beta-lactam enzyme inhibitor by the ratio by weight of 1:2 to 1:0.1, wherein the cefepime is cefepime inner salt, or cefepime hydrochlorate, or cefepime hydrochlorate hydrate, or one of the former medicaments with added adjunct (L-arginine, or sodium carbonate, or sodium hydrogen carbonate, the beta-lactam enzyme inhibitor can be Tazobactam, or clavulanic acid, or tapazole or their derivatives.

The black-bone chicken white phoenix medicine preparation has the functions of invigorating vital energy, nourishing blood, normalize menstruation and arresting bleeding, and is used to treat vital energy and blood deficiency, debility, sourness of waist and legs, dysmenorrhea, and metrorrhagia. It is prepared with black-bone chicken, red sage, oyster, deglued antler powder, astragalus root and other 15 kinds of Chinese medicinal materials and through macroporous resin separation, enzymolysis and other process. It is prepared into concentrated pill, micro pill, granule, tablet, ointment, syrup, mixture, dripping pill or capsule. It has controlled effective component content, raised biological utilization, ensured curative effect and small dosage.

A method for using 3D printing technology produces personalized biomimetic drug-eluting coronary stent and the product thereof. The process of manufacturing stent, based on coronary angiography imaging data, measures the diameter of diseased coronary and conducts 3D reconstruction. A personalized stent for each patient according to diameter, length, and morphological characteristics of target vessel that suited to the lesion is produced. The coronary stent is formed from biodegradable poly-L-lactic acid (PLLA) or other materials. The stent is modeled by 3D printing and then coated with polymers carrying antiproliferative drug to reduce restenosis (the polymers is a mixture of antiproliferative drug and PDLLA at a ratio of 1:1). The biomimetic drug-eluting coronary stent produced by 3D printing technology is personalized stent for each patient according to different characteristics of diseased coronary, reduces the incidence of vascular injury, thrombosis, dissection and other complications caused by stent and vessel diameter mismatch.

The invention relates to a high-purity tazobactam sodium compound, and particularly provides a method for refining the tazobactam sodium compound. The method comprises the following steps: a, dissolving a tazobactam sodium coarse product into water, regulating the pH value of aqueous solution to less than 7 and collecting solid precipitated from the solution; b, dissolving the solid obtained in the step a into organic solvent to obtain solution to be refined; c, putting the solution to be refined into macroporous absorption resin, performing elution and purification by using eluting agent, and collecting eluent; and d, regulating the pH value of the eluent obtained in the step c to 7 and collecting the precipitated solid to obtain refined tazobactam sodium. The refined tazobactam sodium compound prepared by the method has the purity of over 99.8 percent and the yield of over 90 percent.

The invention relates to a reducible and degradable nano medicine-carrying micelle and a preparation method thereof, belonging to the fields of biomedical technology and nano medical technology. The reducible and degradable nano medicine-carrying micelle is characterized by having the following structural general formula: MPEG-CA-PCL, wherein the CA is poly-cystamine containing disulfide bonds, the MPEG is methoxy polyethylene glycol the molecular weight of which is 475-5000DA, and the PCL is polycaprolactone. The preparation method of the reducible and degradable nano medicine-carrying micelle comprises the following steps: (1) carrying out Michael addition to N,N'-bis (acrylic) cystamine and ethanolamine to obtain hydroxy poly-cystamine containing disulfide bonds, and then, carrying out ring opening reaction on caprolactone by utilizing a hydroxy group to obtain a CA-PCL polymer; and (2) mixing the CA-PCL polymer obtained in the step (1) and carboxyl-terminated MPEG, and adding paclitaxel (PTX) to prepare the nano medicine-carrying micelle through a dialysis method. The method is efficient and simple.

The present invention provides inhibitors of protein kinases comprising a molecule having at least a first moiety competent for penetration of the molecule into cells, and a second moiety for having a protein kinase inhibiting effect within the cells. The first moiety is joined to the second moiety through a linker or a spacer. The complex molecules are preferably peptide conjugates having improved cell-permeability, serum stability and kinase selectivity compared to known protein kinase inhibitors. Pharmaceutical compositions that include these protein kinase inhibitors, and methods of using such compositions for treatment of cancers and other diseases associated with protein kinase activity are also disclosed.

The invention discloses a method for preparing a personalized bionic drug eluting coronary stent by using a 3D printing technology and a product. The method for preparing the personalized bionic drug eluting coronary stent comprises the step that according to image data of coronary angiogram, adopting a QCA technique for measuring the diameter of a diseased coronary artery and reconstructing in a three-dimensional manner. According to indexes such as lesion vascular diameter, lesion length and lesion vascular pattern, a personalized coronary stent can be made for each patient in a customized manner and a stent most suitable for the lesion state of a patient can be prepared. The personalized bionic drug eluting coronary stent can be made of degradable poly L-lactic acid (PLLA) or other materials, after 3D printing molding, the surface of the stent can be coated with a polymer with anti-proliferation medicines by using a conventional process, and in-stent restenosis can be reduced (the polymer is prepared by mixing a medicine with PDLLA in a ratio of the medicine to PDLLA being 1:1). The most suitable personalized bionic drug eluting coronary stent can be customized for the patient according to diseased coronary arteries of different states, requirements of different lesions can be met, customization of coronary stents can be achieved, and complications such as vascular injury, thrombus and coronary arterial dissection caused by mismatching of the diameter of the stent and that of the blood vessel can be reduced.

The invention discloses a thermosensitive moxibustion moxa stick capable of efficiently stimulating meridian qi transmission and a preparation method thereof. The thermosensitive moxibustion moxa stick is prepared by refining raw materials of moxa leaves, ligusticum wallichii, notopterygium root, radix angelicae pubescentis and asarum by a certain method, wherein, each moxa stick comprises the following raw materials in parts by weight: 40-60 parts of moxa punk, 4-9 parts of the ligusticum wallichii, 1-5 parts of the notopterygium root, 1-5 parts of theradix angelicae pubescentis and 1-5 parts of the asarum; and the diameter of each moxa stick is 20-42 mm. The invention has strong softness and penetrating power, can dredge meridians and collaterals, efficiently stimulates the meridian qi transmission to generate thermosensitive moxibustion sense, such as diathermancy, heat expansion and heat transmission and the like, greatly improves the clinical efficacies, lowers the wastes of medicinal materials, lightens the economic burden of patients, and has the advantages of easily purchased raw materials, easy processing and simple preparation.

A reference phantom includes CT-imageable detail together with light-reflective spheres. This item can be placed on a patient table in a known location, following which the diagnostic source can be activated to detect the phantom position relative to the isocentre and camera employed to detect the PSS position. A synthetic image of the phantom can be used for comparison with the CT dataset. This allows improved correlation of the source and the patient support, enable further steps to be taken in enhancing the clinical effectiveness of the apparatus. In-use variations of the isocentre location can be corrected in real time by adjustment of the patient support. Thus, as the isocentre moves, the patient can be moved so as to track the moving isocentre. The linac arm could also be designed differently, as the existing design constraint (that isocentre movement must be limited as far as possible) could potentially be relaxed in order to achieve other aims.

Compounds of the following formula:wherein X is H or substituted withwith at least one X being substituted; and halo is fluorine, chlorine, bromine, iodine; and stereoisomers and conjugable analogs thereof.

The invention relates to a traditional Chinese medicine combination for treating fracture, hairline fracture and traumatic injury. The combination is prepared from internal and external medicines. The bulk pharmaceutical chemicals of the internal medicines comprise nux vomica, Chinese angelica, szechuan lovage rhizome, notoginseng, common club moss herb, rhizoma drynariae, himalayan teasel root, salvia miltiorrhiza, rhizoma corydalis and madder. The bulk pharmaceutical chemicals of the external medicines comprises dragon's blood, realgar, red flower, catecholamine, cinnabar, frankincense, myrrh, Chinese angelica root, paris polyphylla, borneol and musk. The external medicines of the invention have an effect of reducing swelling, and the internal medicines thereof have the effects of tonifying kidney and dredging collaterals, promoting reunion of fractured tendons and bones, and strengthening the therapeutic effect. The traditional Chinese medicine combination for treating fracture, hairline fracture and traumatic injury provided by the invention has the advantages of reasonable combination, fast quick effect taking, high cure rate and no toxic side effect, and is suitable for the treatment of various fracture, hairline fracture and traumatic injury. Soft tissue injury, flesh bruises caused by traumatic injury and back bruises can be cured by internal or external taking, while the fracture, comminuted fracture or broken bone dislocation can be effectively treated by internal and external taking. Therefore, good therapeutic effect is provided for comminuted fracture or broken bone dislocation not being cured for a long time after surgeries in the hospital.

The invention relates to an antitumor cell immunotherapy technology, in particular to preparation of a specific tumor killing cell. The preparation method disclosed by the invention comprises the following steps of: 1, sampling a single prokaryotic cell from peripheral blood; 2, separating a DC (Dendritic Cell) from a T cell; 3, maturing the DC and preparing a DC vaccine; 4, preparing a CIK (Cytokine Induced Killer); 5, preparing a CTL (cytotoxic T lymphocyte); and 6, preparing a specific DC-CIK-CTL cell preparation.

The invention relates to a high-purity sodium rabeprazole compound, belonging to the technical field of medicine. The method includes the following steps: dissolving crude sodium rabeprazole synthesized by the reaction of rabeprazole and sodium hydroxide in water, adjusting pH value to be faintly acid to neutral by using solid acid salt, and collecting precipitated solid; after dissolving the solid with organic solvent, conducting elution and purification by using eluting agent through macroporous adsorption resin, and collecting eluent; and adjusting the pH value of the eluent to be alkaline, and collecting the precipitated solid to obtain the pure sodium rabeprazole.

The invention discloses a method for efficiently amplifying NK cells, in particular to a method for efficiently amplifying NK cells using K562 engineered cells of high expression membrane proteins CD19, CD137L, CD86, CD64 and transmembrane protein IL- 21 and combining with human IL-2 mutants. The method has the advantages of simple operation, low cost, large number of obtained NK cells, high purity and good killing effect; the method is suitable for large-scale preparation of the NK cells and lays a good foundation for the application of NK cell adoptive immunotherapy in clinical practice.